There are 3164 resources available
1597MO - Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Dana Rathkopf
Session: Mini oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA10, LBA11 and LBA13
Presenter: Elgene Lim
Session: Proffered paper session: Breast cancer, early stage
Resources:
Slides
Webcast
999MO - HARE-40: A phase I/II trial of therapeutic HPV vaccine (BNT113) in patients with HPV16 driven carcinoma
Presenter: Christian Ottensmeier
Session: Mini oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
LBA72 - Nivolumab 3mg/kg and ipilimumab 1mg/kg (nivo3/ipi1) in molecularly selected patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Niven Mehra
Session: Mini oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
Q&A
Session: Proffered paper session: Breast cancer, early stage
Resources:
Webcast
Invited Discussant 1597MO and LBA72
Presenter: Christopher Sweeney
Session: Mini oral session: GU tumours, prostate
Resources:
Slides
Webcast
1000MO - A phase I/II, open-label study of the novel checkpoint IGSF8 inhibitor GV20-0251 in patients with advanced solid tumors
Presenter: Kristopher Wentzel
Session: Mini oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1001MO - Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR bispecific, in phase I dose escalation
Presenter: Martin Wermke
Session: Mini oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
Invited Discussant 999MO, 1000MO and 1001MO
Presenter: Anna Di Giacomo
Session: Mini oral session: Investigational immunotherapy
Resources:
Slides
Webcast
Presentation by Expert
Presenter: Isabelle Ray-Coquard
Session: New first-line ovarian cancer data: How this will impact first line and relapse treatment?
Resources:
Slides
Webcast